BR112022010806A2 - Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama - Google Patents

Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama

Info

Publication number
BR112022010806A2
BR112022010806A2 BR112022010806A BR112022010806A BR112022010806A2 BR 112022010806 A2 BR112022010806 A2 BR 112022010806A2 BR 112022010806 A BR112022010806 A BR 112022010806A BR 112022010806 A BR112022010806 A BR 112022010806A BR 112022010806 A2 BR112022010806 A2 BR 112022010806A2
Authority
BR
Brazil
Prior art keywords
breast cancer
methods
development
tumor growth
delay
Prior art date
Application number
BR112022010806A
Other languages
English (en)
Inventor
O'hara Lauchle Jennifer
Joseph Mamounas Michael
Lee Schutzman Jennifer
Sickels Friedman Lori
Huang Jian
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112022010806A2 publication Critical patent/BR112022010806A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

MÉTODOS PARA TRATAR CÂNCER DE MAMA, PARA INIBIR O CRESCIMENTO TUMORAL E PARA PREVENIR OU RETARDAR O DESENVOLVIMENTO DE RESISTÊNCIA DE UM CÂNCER DE MAMA. São fornecidas terapias de combinação compreendendo um inibidor de PI3K (por exemplo, inavolisibe), um inibidor de CDK4/6 (por exemplo, palbociclibe) e fulvestranto; e métodos para tratar câncer de mama localmente avançado ou metastático positivo para receptor hormonal e negativo para HER2 (HR+/HER2-) em um paciente (de preferência um paciente com um mutante PIC3CA) compreendendo a administração de uma quantidade terapeuticamente eficaz de inavolisibe, ou um sal farmaceuticamente aceitável do mesmo, um inibidor de CDK4/6 (por exemplo, palbociclibe) e fulvestranto ou letrozol.
BR112022010806A 2019-12-03 2020-12-01 Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama BR112022010806A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962943185P 2019-12-03 2019-12-03
US201962946400P 2019-12-10 2019-12-10
US202063014965P 2020-04-24 2020-04-24
PCT/US2020/062673 WO2021113219A1 (en) 2019-12-03 2020-12-01 Combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR112022010806A2 true BR112022010806A2 (pt) 2022-08-23

Family

ID=74068683

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010806A BR112022010806A2 (pt) 2019-12-03 2020-12-01 Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama

Country Status (12)

Country Link
US (1) US20230088701A1 (pt)
EP (1) EP4069218A1 (pt)
JP (1) JP2023504436A (pt)
KR (1) KR20220108085A (pt)
CN (1) CN114786666A (pt)
AU (1) AU2020396093A1 (pt)
BR (1) BR112022010806A2 (pt)
CA (1) CA3156205A1 (pt)
IL (1) IL293347A (pt)
MX (1) MX2022006566A (pt)
TW (1) TW202133857A (pt)
WO (1) WO2021113219A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107873032B (zh) 2015-07-02 2020-07-17 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
KR20230137379A (ko) * 2021-01-29 2023-10-04 메드샤인 디스커버리 아이엔씨. 삼중 융합 고리계 화합물 및 이의 용도
WO2023051725A1 (zh) * 2021-09-30 2023-04-06 广州嘉越医药科技有限公司 一种药物组合及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4978672A (en) 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
WO2003062236A1 (en) 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
EP1648889B1 (en) 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
CN107873032B (zh) * 2015-07-02 2020-07-17 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2020023297A1 (en) * 2018-07-23 2020-01-30 Genentech, Inc. Methods of treating cancer with pi3k inhibitor, gdc-0077
WO2020076432A1 (en) * 2018-10-08 2020-04-16 Genentech, Inc. Methods of treating cancer with pi3k alpha inhibitors and metformin

Also Published As

Publication number Publication date
TW202133857A (zh) 2021-09-16
KR20220108085A (ko) 2022-08-02
AU2020396093A1 (en) 2022-05-19
CA3156205A1 (en) 2021-06-10
CN114786666A (zh) 2022-07-22
IL293347A (en) 2022-07-01
WO2021113219A1 (en) 2021-06-10
US20230088701A1 (en) 2023-03-23
MX2022006566A (es) 2022-07-01
JP2023504436A (ja) 2023-02-03
EP4069218A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
BR112022010806A2 (pt) Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama
JP2017039771A5 (pt)
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
MX2022015695A (es) Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2021000726A (es) Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
PH12021551023A1 (en) Methods for shrinking pituitary tumors
Bokobza et al. Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer
WO2020033838A3 (en) Treatment of egfr-mutant cancer
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
Konopka-Filippow et al. Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
WO2015035410A8 (en) Cancer therapy